RecruitingNCT05902039

MRI Study of Blood-brain Barrier Function in CADASIL


Sponsor

Peking University First Hospital

Enrollment

100 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Diffusion prepared pseudo-continuous ASL (DP-pCASL) is a newly proposed MRI method to noninvasively measure the function of blood-brain barrier (BBB). The investigators aim to investigate whether the water exchange rate across the BBB, estimated with DP-pCASL, is changed in patients with CADASIL, and to analyze the association between BBB water exchange rate and MRI/clinical features in these patients.


Eligibility

Min Age: 20 YearsMax Age: 70 Years

Inclusion Criteria3

  • Patients with CADASIL confirmed by gene or/and skin biopsy.
  • The age range is 20-70 years old.
  • There is no contraindication to MRI examination, and the informed consent is signed.

Exclusion Criteria3

  • Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.
  • CADASIL is not confirmed.
  • There are contraindications to examination or refusal to sign the informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMRI

All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.


Locations(1)

Peking University First Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05902039


Related Trials